TY - JOUR A1 - von Kries, Rüdiger A1 - Weiss, Susanne A1 - Falkenhorst, Gerhard A1 - Wirth, Stephan A1 - Kaiser, Petra A1 - Huppertz, Hans-Iko A1 - Tenenbaum, Tobias A1 - Schroten, Horst A1 - Streng, Andrea A1 - Liese, Johannes A1 - Shai, Sonu A1 - Niehues, Tim A1 - Girschick, Hermann A1 - Kuscher, Ellen A1 - Sauerbrey, Axel A1 - Peters, Jochen A1 - Wirsing von Koenig, Carl Heinz A1 - Rückinger, Simon A1 - Hampl, Walter A1 - Michel, Detlef A1 - Mertens, Thomas T1 - Post-Pandemic Seroprevalence of Pandemic Influenza A (H1N1) 2009 Infection (Swine Flu) among Children < 18 Years in Germany JF - PLoS ONE N2 - Background: We determined antibodies to the pandemic influenza A (H1N1) 2009 virus in children to assess: the incidence of (H1N1) 2009 infections in the 2009/2010 season in Germany, the proportion of subclinical infections and to compare titers in vaccinated and infected children. Methodology/Principal Findings: Eight pediatric hospitals distributed over Germany prospectively provided sera from in-or outpatients aged 1 to 17 years from April 1(st) to July 31(st) 2010. Vaccination history, recall of infections and sociodemographic factors were ascertained. Antibody titers were measured with a sensitive and specific in-house hemagglutination inhibition test (HIT) and compared to age-matched sera collected during 6 months before the onset of the pandemic in Germany. We analyzed 1420 post-pandemic and 300 pre-pandemic sera. Among unvaccinated children aged 1-4 and 5-17 years the prevalence of HI titers (>= 1:10) was 27.1% (95% CI: 23.5-31.3) and 53.5% (95% CI: 50.9-56.2) compared to 1.7% and 5.5%, respectively, for pre-pandemic sera, accounting for a serologically determined incidence of influenza A (H1N1) 2009 during the season 2009/2010 of 25,4% (95% CI : 19.3-30.5) in children aged 1-4 years and 48.0% (95% CI: 42.6-52.0) in 5-17 year old children. Of children with HI titers >= 1: 10, 25.5% (95% CI: 22.5-28.8) reported no history of any infectious disease since June 2009. Among vaccinated children, 92% (95%-CI: 87.0-96.6) of the 5-17 year old but only 47.8% (95%-CI: 33.5-66.5) of the 1-4 year old children exhibited HI titers against influenza A virus (H1N1) 2009. Conclusion: Serologically determined incidence of influenza A (H1N1) 2009 infections in children indicates high infection rates with older children (5-17 years) infected twice as often as younger children. In about a quarter of the children with HI titers after the season 2009/2010 subclinical infections must be assumed. Low HI titers in young children after vaccination with the AS03(B)-adjuvanted split virion vaccine need further scrutiny. KW - Hemagglutination inhibition KW - Vaccine KW - Age KW - Immunogenicity KW - Prevalence KW - Antibody KW - Viruses KW - England KW - Safety KW - Risk Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141698 VL - 6 IS - 9 ER - TY - JOUR A1 - Hanitsch, Leif A1 - Baumann, Ulrich A1 - Boztug, Kaan A1 - Burkhard‐Meier, Ulrike A1 - Fasshauer, Maria A1 - Habermehl, Pirmin A1 - Hauck, Fabian A1 - Klock, Gerd A1 - Liese, Johannes A1 - Meyer, Oliver A1 - Müller, Rainer A1 - Pachlopnik‐Schmid, Jana A1 - Pfeiffer‐Kascha, Dorothea A1 - Warnatz, Klaus A1 - Wehr, Claudia A1 - Wittke, Kirsten A1 - Niehues, Tim A1 - von Bernuth, Horst T1 - Treatment and management of primary antibody deficiency: German interdisciplinary evidence‐based consensus guideline JF - European Journal of Immunology N2 - This evidence‐based clinical guideline provides consensus‐recommendations for the treatment and care of patients with primary antibody deficiencies (PADs). The guideline group comprised 20 clinical and scientific expert associations of the German, Swiss, and Austrian healthcare system and representatives of patients. Recommendations were based on results of a systematic literature search, data extraction, and evaluation of methodology and study quality in combination with the clinical expertise of the respective representatives. Consensus‐based recommendations were determined via nominal group technique. PADs are the largest clinically relevant group of primary immunodeficiencies. Most patients with PADs present with increased susceptibility to infections, however immune dysregulation, autoimmunity, and cancer affect a significant number of patients and may precede infections. This guideline therefore covers interdisciplinary clinical and therapeutic aspects of infectious (e.g., antibiotic prophylaxis, management of bronchiectasis) and non‐infectious manifestations (e.g., management of granulomatous disease, immune cytopenia). PADs are grouped into disease entities with definitive, probable, possible, or unlikely benefit of IgG‐replacement therapy. Summary and consensus‐recommendations are provided for treatment indication, dosing, routes of administration, and adverse events of IgG‐replacement therapy. Special aspects of concomitant impaired T‐cell function are highlighted as well as clinical data on selected monogenetic inborn errors of immunity formerly classified into PADs (APDS, CTLA‐4‐, and LRBA‐deficiency). KW - autoimmunity KW - CVID KW - hypogammaglobulinemia KW - immunoglobulins KW - primary antibody deficiency Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225731 VL - 50 IS - 10 SP - 1432 EP - 1446 ER -